Moderna Inc - Asset Resilience Ratio
Moderna Inc (MRNA) has an Asset Resilience Ratio of 28.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MRNA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Moderna Inc's Asset Resilience Ratio has changed over time. See Moderna Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Moderna Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MRNA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.30 Billion | 28.7% |
| Total Liquid Assets | $3.30 Billion | 28.70% |
Asset Resilience Insights
- Very High Liquidity: Moderna Inc maintains exceptional liquid asset reserves at 28.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Moderna Inc Industry Peers by Asset Resilience Ratio
Compare Moderna Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
Annual Asset Resilience Ratio for Moderna Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Moderna Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.97% | $3.20 Billion | $12.34 Billion | -10.08pp |
| 2024-12-31 | 36.05% | $5.10 Billion | $14.14 Billion | +5.13pp |
| 2023-12-31 | 30.92% | $5.70 Billion | $18.43 Billion | +5.02pp |
| 2022-12-31 | 25.90% | $6.70 Billion | $25.86 Billion | +10.17pp |
| 2021-12-31 | 15.72% | $3.88 Billion | $24.67 Billion | -11.32pp |
| 2020-12-31 | 27.04% | $1.98 Billion | $7.34 Billion | -27.51pp |
| 2019-12-31 | 54.56% | $867.12 Million | $1.59 Billion | +10.57pp |
| 2018-12-31 | 43.99% | $863.06 Million | $1.96 Billion | -13.29pp |
| 2017-12-31 | 57.28% | $621.17 Million | $1.08 Billion | -13.85pp |
| 2016-12-31 | 71.13% | $1.01 Billion | $1.42 Billion | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more